A forensic blueprint for truth, security, accountabilityIn an era where crime has become increasingly mobile, digital and identity-driven, the ability to reliably establish who is who has become one ...

Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results topping the market’s revenue expectations, but sales ...

Asian carp are large, voracious, and invasive. After their introduction to the United States during the early 1970s to ...

NEB's collaborative approach is built on close work with laboratory automation partners to automate, optimize and verify ...

NEB's collaborative approach is built on close work with laboratory automation partners to automate, optimize and verify performance across a wide range of NEBNext products, including NEBNext ...

Mass spectrometry (MS) has long been a cornerstone of chemical and biological analysis, but in biotech and biomanufacturing, it is now experiencing a renaissance. As drug modalities diversify—peptides ...

The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...

Financially, Azenta maintains a robust position. The company holds $571 million in cash and marketable securities and carries no debt, providing substantial flexibility for future strategic ...

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.

The Midwest Creation Fellowship presents Dr. Paul Nelson from Logos Research Associates and Biola University on Feb. 9.

Although there are striking differences between the cells that make up your eyes, kidneys, brain and toes, the DNA blueprint for these cells is essentially the same. Where do those differences come ...